US FDA OK's expanded Eribitux use, Qiagen KRAS test
This article was originally published in Scrip
Executive Summary
With the US FDA giving its nod to Qiagen's therascreen KRAS diagnostic kit on 6 July, the agency also gave its blessing to Lilly and Bristol-Myers Squibb to market Erbitux (cetuximab) in combination with the chemotherapy regimen FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) as a first-line treatment for patients with KRAS mutation-negative, epidermal-growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC), based on results using the test.